![San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce](https://c8.alamy.com/comp/PW5TY8/san-polo-di-torrile-italy-12th-october-2018-managers-and-workers-of-gsk-and-italian-authorities-inaugurate-the-new-plant-to-produce-fostemsavir-innovative-drug-for-treatment-resistant-hiv-patients-gsk-will-produce-fostemsavir-on-behalf-of-viiv-healthcare-the-global-specialist-hiv-company-majority-owned-by-glaxosmithkline-with-pfizer-inc-and-shionogi-limited-as-shareholders-gonewiththewindalamy-live-news-PW5TY8.jpg)
San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce
![Gsk, 30 milioni di euro per un nuovo impianto a San Polo di Torrile: produrrà un farmaco sperimentale contro l'HIV Gsk, 30 milioni di euro per un nuovo impianto a San Polo di Torrile: produrrà un farmaco sperimentale contro l'HIV](https://www.parmatoday.it/~media/horizontal-hi/6197579984943/gsk-2.jpg)
Gsk, 30 milioni di euro per un nuovo impianto a San Polo di Torrile: produrrà un farmaco sperimentale contro l'HIV
![EDITORIAL, GSK Plant for New Anti-HIV Drug Editorial Stock Photo - Image of viiv, italian: 128728898 EDITORIAL, GSK Plant for New Anti-HIV Drug Editorial Stock Photo - Image of viiv, italian: 128728898](https://thumbs.dreamstime.com/z/san-polo-di-torrile-italy-october-sunight-enlightening-gsk-logo-plant-fostemsavir-innovative-anti-hiv-drug-day-128728898.jpg)
EDITORIAL, GSK Plant for New Anti-HIV Drug Editorial Stock Photo - Image of viiv, italian: 128728898
![Gsk, 113 milioni di investimenti per il biotech di Parma (anche per la lotta contro il Covid)- Corriere.it Gsk, 113 milioni di investimenti per il biotech di Parma (anche per la lotta contro il Covid)- Corriere.it](https://images2.corriereobjects.it/methode_image/2020/12/07/Economia/Foto%20Economia%20-%20Trattate/glaxo4-kQwB-U3230193066013YP-320x240@Corriere-Web-Sezioni.jpg?v=202012071502)
Gsk, 113 milioni di investimenti per il biotech di Parma (anche per la lotta contro il Covid)- Corriere.it
![San Polo Di Torrile, Italy - October 12, 2018: Luis Arosemena, President And CEO At GSK Italy, Speaks At The Inauguration Of The Plant To Produce Fostemsavir, Innovative Anti-HIV Drug Stock Photo, Picture And Royalty Free Image. Image 110267966. San Polo Di Torrile, Italy - October 12, 2018: Luis Arosemena, President And CEO At GSK Italy, Speaks At The Inauguration Of The Plant To Produce Fostemsavir, Innovative Anti-HIV Drug Stock Photo, Picture And Royalty Free Image. Image 110267966.](https://us.123rf.com/450wm/gonewiththewind/gonewiththewind1810/gonewiththewind181000528/110267966-san-polo-di-torrile-italy-october-12-2018-luis-arosemena-president-and-ceo-at-gsk-italy.jpg)
San Polo Di Torrile, Italy - October 12, 2018: Luis Arosemena, President And CEO At GSK Italy, Speaks At The Inauguration Of The Plant To Produce Fostemsavir, Innovative Anti-HIV Drug Stock Photo, Picture And Royalty Free Image. Image 110267966.
![San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce](https://c8.alamy.com/comp/PW5TY5/san-polo-di-torrile-italy-12th-october-2018-managers-and-workers-of-gsk-and-italian-authorities-inaugurate-the-new-plant-to-produce-fostemsavir-innovative-drug-for-treatment-resistant-hiv-patients-gsk-will-produce-fostemsavir-on-behalf-of-viiv-healthcare-the-global-specialist-hiv-company-majority-owned-by-glaxosmithkline-with-pfizer-inc-and-shionogi-limited-as-shareholders-gonewiththewindalamy-live-news-PW5TY5.jpg)
San Polo di Torrile, Italy. 12th October, 2018. Managers and workers of GSK and Italian authorities inaugurate the new plant to produce Fostemsavir, innovative drug for treatment-resistant HIV patients. GSK will produce
![San Polo di Torrile, Italy. 12th October, 2018. GSK and VIIV flags waving together in San Polo di Torrile plant. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist San Polo di Torrile, Italy. 12th October, 2018. GSK and VIIV flags waving together in San Polo di Torrile plant. GSK will produce Fostemsavir on behalf of ViiV Healthcare, the global specialist](https://c8.alamy.com/comp/PW64G3/san-polo-di-torrile-italy-12th-october-2018-gsk-and-viiv-flags-waving-together-in-san-polo-di-torrile-plant-gsk-will-produce-fostemsavir-on-behalf-of-viiv-healthcare-the-global-specialist-hiv-company-majority-owned-by-glaxosmithkline-with-pfizer-inc-and-shionogi-limited-as-shareholders-gonewiththewindalamy-live-news-PW64G3.jpg)